ArticleCancer medicine2025
Hepatitis B Virus X Protein Upregulates SREBP2 to Modulate Autophagy in Hepatocellular Carcinoma.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lipid metabolism in cancer cells: Its role in hepatocellular carcinoma progression and therapeutic resistance.Hepatology communications · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe interaction between Hepatitis B virus X protein (HBx) and sterol regulatory element binding protein 2 (SREBP2) in modulating autophagy to influence inflammation and tumorigenesis is not fully understood. This research seeks to clarify the regulatory role of HBx in hepatocyte autophagy through SREBP2.
methodsThe study employed TCGA and GEO databases to investigate the expression of SREBF2 and autophagy-related proteins in liver cancer. Various experimental techniques, including dual-luciferase reporter assays, immunohistochemistry, Western blotting, immunofluorescence, GFP-mRFP-LC3 puncta analysis, transmission electron microscopy, and Fillipin III staining, were conducted on HBV-associated liver cancer tissues, HBV transgenic mice, and several liver cancer cell lines to assess the levels of HBx, SREBP2, autophagy, and cholesterol, respectively, as well as to explore potential associations between these factors.
resultsBioinformatics analysis suggested up-regulation of SREBP2 and autophagy-associated genes in HBV-associated liver cancer. Elevated levels of cholesterol, SREBP2, and autophagy flux were detected in HBV-associated liver cancer tissues as compared to adjacent tissues. HBV transgenic mice had higher cholesterol, SREBP2, and autophagy levels than wild-type mice. HBx activated the SREBP2 promoter to enhance its transcription and nuclear translocation. HBx knockdown down-regulated SREBP2 expression and nuclear translocation levels in HepG2.2.15-siHBx cells. HepG2.2.15 and HepG2-HBx showed more autolysosomes than HepG2 cells; furthermore, HepG2.2.15-siHBx cells had fewer autolysosomes than HepG2.2.15 cells.
conclusionsThis research highlights that HBx upregulates SREBP2 and increases autophagic flux, accompanied by changes in cholesterol metabolism, which offers an additional theoretical foundation to elucidate that chronic HBV infection causes abnormal lipid metabolism and induces tumorigenesis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.